Immunotech Biopharm Ltd (HKG:6978)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
3.390
-0.240 (-6.61%)
Apr 17, 2026, 4:08 PM HKT
Market Cap2.24B +3.2%
Revenue (ttm)n/a
Net Income-256.82M
EPS-0.47
Shares Out617.50M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,446,018
Average Volume599,406
Open3.570
Previous Close3.630
Day's Range3.200 - 3.570
52-Week Range2.300 - 5.830
Beta0.52
RSI65.22
Earnings DateMar 20, 2026

About Immunotech Biopharm

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People’s Republic of China. The company’s core product is EAL, a multi-target cellular immunotherapy product that is in Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. It also develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 183
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6978
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements